J Antimicrob Chemother. 2005 Aug;56(2):273-6. Epub 2005 Jun 30.

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

Source

Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA.

Abstract

Protease inhibitor-based antiretroviral therapy has been shown to decrease the morbidity and mortality associated with human immunodeficiency virus type 1 (HIV-1) infection. However, many of the available agents in this class suffer shortcomings, including poor tolerability, difficult dosing regimens, and variable drug concentrations which may lead to generation of viral resistance. Lopinavir/ritonavir (Kaletra) has been designed specifically to address some of these shortcomings. Excellent therapeutic efficacy has been documented for lopinavir/ritonavir in multiple clinical trials in both antiretroviral-naive and -experienced patients. Development of resistance is a rare event in persons initiating therapy with lopinavir/ritonavir as their first protease inhibitor. The main side effects associated with lopinavir/ritonavir are gastrointestinal disturbances and elevations of serum lipids. Current antiretroviral therapy guidelines list lopinavir/ritonavir as the consensus first-line protease inhibitor recommended in the initial therapeutic regimen in persons infected with HIV-1.

PMID:: 15994247; [PubMed - indexed for MEDLINE]

Free full text

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. [Expert Opin Pharmacother. 2005]
Review Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
Kaplan SS, Hicks CB. Expert Opin Pharmacother. 2005 Aug; 6(9):1573-85.
Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. [Pediatr Infect Dis J. 2005]
Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, et al. Pediatr Infect Dis J. 2005 Oct; 24(10):867-73.
Review Lopinavir/ritonavir: appraisal of its use in HIV therapy. [Drugs Today (Barc). 2007]
Review Lopinavir/ritonavir: appraisal of its use in HIV therapy.
von Hentig N. Drugs Today (Barc). 2007 Apr; 43(4):221-47.
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. [J Virol. 2005]
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. J Virol. 2005 Mar; 79(6):3329-38.
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. [Clin Infect Dis. 2005]
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B. Clin Infect Dis. 2005 Oct 15; 41(8):1186-95. Epub 2005 Sep 13.

See reviews... See all...

Cited by 1 PubMed Central article

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. [AIDS Res Ther. 2009]
Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.
Manosuthi W, Kiertiburanakul S, Amornnimit W, Prasithsirikul W, Thongyen S, Nilkamhang S, Ruxrungtham K, Sungkanuparph S. AIDS Res Ther. 2009 Dec 23; 6:30. Epub 2009 Dec 23.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immu...
Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
J Antimicrob Chemother. 2005 Aug ;56(2):273-6. Epub 2005 Jun 30 .

PubMed
Beyond the brush border: NHERF4 blazes new NHERF turf.
Beyond the brush border: NHERF4 blazes new NHERF turf.
J Physiol. 2005 Aug 15 ;567(Pt 1):13-9. Epub 2005 Jul 1 .

PubMed
Morbidity after sentinel lymph node biopsy in primary breast cancer: results fro...
Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial.
J Clin Oncol. 2005 Jul 1 ;23(19):4312-21.

PubMed
Inter-examiner reliability of passive assessment of intervertebral motion in the...
Inter-examiner reliability of passive assessment of intervertebral motion in the cervical and lumbar spine: a systematic review.
Man Ther. 2005 Nov ;10(4):256-69. Epub 2005 Jul 1 .

PubMed
The prevalence of PIK3CA mutations in gastric and colon cancer.
The prevalence of PIK3CA mutations in gastric and colon cancer.
Eur J Cancer. 2005 Jul ;41(11):1649-54.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information